Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are both highly respected pharmaceutical companies. However, their stock ...

Eli Lilly and Company’s LLY stock has risen 18% in a month, driven mainly by a stellar third-quarter performance. Also, earlier this month, President Trump announced deals with Lilly and rival Novo ...

Eli Lilly stock has soared in the triple digits over three years. Investors are excited about the company’s portfolio of weight loss drugs, which has generated blockbuster revenue. Investors generally ...

J. L. Bainbridge & Co. bought 61,258 shares of Eli Lilly and Company for an estimated $45.6 million in the third quarter. Post-transaction, the wealth advisory reported owning 61,782 shares of Eli ...

Lilly has already submitted the combination data for US regulatory review in ESR1-mutated metastatic breast cancer. Additionally, imlunestrant is being studied in the EMBER-4 trial, which has enrolled ...

FDA oral Wegovy, solid fundamentals, and low P/E vs. Eli Lilly. Click for this updated look at NVO stock prospects as ...

Eli Lilly And Co (NASDAQ: LLY) shares are trading down on Tuesday as investors weigh the competitive landscape in the pharmaceutical sector.

Novo Nordisk’s wildly successful obesity medicine is now available as a pill, making it the first GLP-1 pill for weight loss ...

Eli Lilly LLY reported 54% revenue growth in the third quarter as its diabetes and obesity drug tirzepatide (Mounjaro/Zepbound) continued to gain share globally, and management raised top- and ...

Investors generally don't turn to pharmaceutical stocks with expectations of high growth in a short period of time. Instead, they scoop up these players for their promise of steady gains over the ...